-
Roth Capital Highlights Biotech Picks 'for the Turn' and Over the Long Haul (PTN) (LGND) (TGTX) (CLDX)
-
Celgene/Juno Deal Bodes Well For Lion Biotechnologies (LBIO), Roth Capital Says
-
Multiple Positives Appear from Latest Publication of Lion Biotech's (LBIO) TIL Data - Roth
-
Streetinsider.com's Hot Lunchtime Reads 3/30: (MGA) (YELP) (AAPL) (BBRY)
-
Lion Biotechnologies (LBIO) Receives First External Validation of Phase I TIL/Yervoy in Metastatic Melanoma; Roth Capital Affirms at 'Buy'
-
Pre-Open Stock Movers 02/26: (ELX) (CYBX) (UIL) (CRM) Higher; (CLRX) (LKQ) (TASR) Lower (more...)
-
Lion Biotechnologies (LBIO) Prices 8M Common Offering at $8/Share

